Tamoxifen regulation of bone growth and endocrine function in the ovariectomized rat: Discrimination of responses involving estrogen receptor α/estrogen receptor β, G protein-coupled estrogen receptor, or estrogen-related receptor γ using fulvestrant (ICI 182780)

Journal of Pharmacology and Experimental Therapeutics

Volumn 338, Issue 1, 2011, Pages 246-254

  Fitts, James M ^a   Klein, Robert M ^a   Powers, C Andrew ^a  

^a NEW YORK MEDICAL COLLEGE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ESTROGEN RECEPTOR; ESTROGEN RECEPTOR ALPHA; ESTROGEN RECEPTOR BETA; ESTROGEN RELATED RECEPTOR GAMMA; FULVESTRANT; G PROTEIN COUPLED ESTROGEN RECEPTOR; G PROTEIN COUPLED RECEPTOR; PROLACTIN; SOMATOMEDIN C; TAMOXIFEN; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ARTICLE; BODY WEIGHT; BONE DENSITY; BONE GROWTH; CONTROLLED STUDY; DRUG ANTAGONISM; DRUG EFFECT; FEEDBACK SYSTEM; FEMALE; GROWTH HORMONE BLOOD LEVEL; GROWTH REGULATION; HYPOPHYSIS; HYPOPHYSIS FUNCTION; MALE; MUSCULOSKELETAL SYSTEM PARAMETERS; NONHUMAN; OVARIECTOMY; PRIORITY JOURNAL; RAT; TIBIA; TREATMENT DURATION; UTERUS WEIGHT;

ANIMALS; BONE DENSITY; BONE DEVELOPMENT; ESTRADIOL; ESTROGEN RECEPTOR ALPHA; ESTROGEN RECEPTOR BETA; FEMALE; OVARIECTOMY; PITUITARY GLAND; RANDOM ALLOCATION; RATS; RATS, SPRAGUE-DAWLEY; RECEPTORS, ESTROGEN; RECEPTORS, G-PROTEIN-COUPLED; TAMOXIFEN;

EID: 79959503401     PISSN: 00223565     EISSN: 15210103     Source Type: Journal    
DOI: 10.1124/jpet.110.173955     Document Type: Article

References (55)

1. Alfinito PD, Chen X, Atherton J, Cosmi S, and Deecher DC (2008) ICI 182780 penetrates brain and hypothalamic tissue and has functional effects in the brain after systemic dosing. Endocrinology 149:5219-5226.
2. Blasko E, Haskell CA, Leung S, Gualtieri G, Halks-Miller M, Mahmoudi M, Dennis MK, Prossnitz ER, Karpus WJ, and Horuk R (2009) Beneficial role of the GPR30 agonist G-1 in an animal model of multiple sclerosis. J Neuroimmunol 214:67-77.
3. Bologa CG, Revankar CM, Young SM, Edwards BS, Arterburn JB, Kiselyov AS, Parker MA, Tkachenko SE, Savchuck NP, Sklar LA, et al. (2006) Virtual and biomolecular screening converge on a selective agonist for GPR30. Nat Chem Biol 2:207-212.
4. Bross PF, Cohen MH, Williams GA, and Pazdur R (2002) FDA drug approval summaries: fulvestrant. Oncologist 7:477-480. (Pubitemid 36008996)
5. Coward P, Lee D, Hull MV, and Lehmann JM (2001) 4-Hydroxytamoxifen binds to and deactivates the estrogen-related receptor γ. Proc Natl Acad Sci USA 98:8880-8884. (Pubitemid 32678121)
6. Crawford BA, Martin JL, Howe CJ, Handelsman DJ, and Baxter RC (1992) Comparison of extraction methods for insulin-like growth factor-I in rat serum. J Endocrinol 134:169-176.
7. Curtis Hewitt S, Couse JF, and Korach KS (2000) Estrogen receptor transcription and transactivation: Estrogen receptor knockout mice: what their phenotypes reveal about mechanisms of estrogen action. Breast Cancer Res 2:345-352. (Pubitemid 32223617)
8. De Nicola AF, von Lawzewitsch I, Kaplan SE, and Libertun C (1978) Biochemical and ultrastructural studies on estrogen-induced pituitary tumors in F344 rats. J Natl Cancer Inst 61:753-763. (Pubitemid 9029105)
9. Dennis MK, Burai R, Ramesh C, Petrie WK, Alcon SN, Nayak TK, Bologa CG, Leitao A, Brailoiu E, Deliu E, et al. (2009) In vivo effects of a GPR30 antagonist. Nat Chem Biol 5:421-427.
10. Deschamps AM and Murphy E (2009) Activation of a novel estrogen receptor, GPER, is cardioprotective in male and female rats. Am J Physiol Heart Circ Physiol 297:H1806-H1813.
11. DiPippo VA, Lindsay R, and Powers CA (1995) Estradiol and tamoxifen interactions with thyroid hormone in the ovariectomized-thyroidectomized rat. Endocrinology 136:1020-1033.
12. DiPippo VA and Powers CA (1997) Tamoxifen and ICI 182,780 interactions with thyroid hormone in the ovariectomized-thyroidectomized rat. J Pharmacol Exp Ther 281:142-148.
13. Donath J and Nishino Y (1998) Effects of partial versus pure antiestrogens on ovulation and the pituitary-ovarian axis in the rat. J Steroid Biochem Mol Biol 66:247-254. (Pubitemid 28401699)
14. Fitts JM, Klein RM, and Powers CA (1998) Comparison of tamoxifen effects on the actions of triiodothyronine or growth hormone in the ovariectomized- hypothyroid rat. J Pharmacol Exp Ther 286:392-402. (Pubitemid 28318015)
15. Fitts JM, Klein RM, and Powers CA (2001) Estrogen and tamoxifen interplay with T3 in male rats: pharmacologically distinct classes of estrogen responses affecting growth, bone, and lipid metabolism, and their relation to serum GH and IGF-I. Endocrinology 142:4223-4235. (Pubitemid 32907048)
16. Fitts JM, Klein RM, and Powers CA (2004) Comparison of tamoxifen and testosterone propionate in male rats: differential prevention of orchidectomy effects on sex organs, bone mass, growth, and the growth hormone-IGF-I axis. J Androl 25:523-534. (Pubitemid 38880188)
17. Ford J, Hajibeigi A, Long M, Hahner L, Gore C, Hsieh JT, Clegg D, Zerwekh J, and Oz OK (2011) GPR30 deficiency causes increased bone mass, mineralization, and growth plate proliferative activity in male mice. J Bone Miner Res 26:298-307.
18. Gallagher A, Chambers TJ, and Tobias JH (1993) The estrogen antagonist ICI 182,780 reduces cancellous bone volume in female rats. Endocrinology 133:2787-2791. (Pubitemid 24000737)
19. Gardener HE and Clark AS (2001) Systemic ICI 182,780 alters the display of sexual behaviors in the female rat. Horm Behav 39:121-130. (Pubitemid 32217588)
20. Giguère V (2008) Transcriptional control of energy homeostasis by the estrogenrelated receptors. Endocr Rev 29:677-696.
21. Giustina A and Veldhuis JD (1998) Pathophysiology of the neuroregulation of growth hormone secretion in experimental animals and the human. Endocr Rev 19:717-797. (Pubitemid 128506521)
22. Greschik H, Flaig R, Renaud JP, and Moras D (2004) Structural basis for the deactivation of the estrogen-related receptor gamma by diethylstilbestrol or 4-hydroxytamoxifen and determinants of selectivity. J Biol Chem 279:33639-33646. (Pubitemid 39063013)
23. Greschik H, Wurtz JM, Sanglier S, Bourguet W, van Dorsselaer A, Moras D, and Renaud JP (2002) Structural and functional evidence for ligand-independent transcriptional activation by the estrogen-related receptor 3. Mol Cell 9:303-313. (Pubitemid 34195556)
24. Haas E, Bhattacharya I, Brailoiu E, Damjanović M, Brailoiu GC, Gao X, Mueller-Guerre L, Marjon NA, Gut A, Minotti R, et al. (2009) Regulatory role of G protein-coupled estrogen receptor for vascular function and obesity. Circ Res 104:288-291.
25. Heard DJ, Norby PL, Holloway J, and Vissing H (2000) Human ERRγ, a third member of the estrogen receptor-related receptor (ERR) subfamily of orphan nuclear receptors: tissue-specific isoforms are expressed during development and in the adult. Mol Endocrinol 14:382-392. (Pubitemid 32260530)
26. Holtzman S, Stone JP, and Shellabarger CJ (1979) Influence of diethylstilbestrol treatment on prolactin cells of female ACI and Sprague-Dawley rats. Cancer Res 39:779-784. (Pubitemid 9143263)
27. Ignatov T, Eggemann H, Semczuk A, Smith B, Bischoff J, Roessner A, Costa SD, Kalinski T, and Ignatov A (2010) Role of GPR30 in endometrial pathology after tamoxifen for breast cancer. Am J Obstet Gynecol 203:595.e9-e16.
28. James AW, Theologis AA, Brugmann SA, Xu Y, Carre AL, Leucht P, Hamilton K, Korach KS, and Longaker MT (2009) Estrogen/estrogen receptor α signaling in mouse posterofrontal cranial suture fusion. PLoS One 4:e7120.
29. Kalu DN (1991) The ovariectomized rat model of postmenopausal bone loss. Bone Miner 15:175-191.
30. Leung KC, Johannsson G, Leong GM, and Ho KK (2004) Estrogen regulation of growth hormone action. Endocr Rev 25:693-721. (Pubitemid 39366048)
31. Li Y, Birnbaumer L, and Teng CT (2010) Regulation of ERRα gene expression by estrogen receptor agonists and antagonists in SKBR3 breast cancer cells: differential molecular mechanisms mediated by G-protein-coupled receptor GPR30/GPER-1. Mol Endocrinol 24:969-980.
32. Lindsey SH, Cohen JA, Brosnihan KB, Gallagher PE, and Chappell MC (2009) Chronic treatment with the G protein-coupled receptor 30 agonist G-1 decreases blood pressure in ovariectomized mRen2.Lewis rats. Endocrinology 150:3753-3758.
33. Lucas TF, Royer C, Siu ER, Lazari MF, and Porto CS (2010) Expression and signaling of G protein-coupled estrogen receptor l (GPER) in rat sertoli cells. Biol Reprod 83:307-317.
34. Mårtensson UE, Salehi SA, Windahl S, Gomez MF, Swärd K, Daszkiewicz-Nilsson J, Wendt A, Andersson N, Hellstrand P, Grände PO, et al. (2009) Deletion of the G protein-coupled receptor 30 impairs glucose tolerance, reduces bone growth, increases blood pressure, and eliminates estradiol-stimulated insulin release in female mice. Endocrinology 150:687-698.
35. McDonnell DP, Connor CE, Wijayaratne A, Chang CY, and Norris JD (2002) Definition of the molecular and cellular mechanisms underlying the tissue-selective agonist/antagonist activities of selective estrogen receptor modulators. Recent Prog Horm Res 57:295-316.
36. Nicholson RI, Gee JM, Manning DL, Wakeling AE, Montano MM, and Katzenellenbogen BS (1995) Responses to pure antiestrogens (ICI 164384, ICI 182780) in estrogen-sensitive and -resistant experimental and clinical breast cancer. Ann NY Acad Sci 761:148-163.
37. Osborne CK, Wakeling A, and Nicholson RI (2004) Fulvestrant: an oestrogen receptor antagonist with a novel mechanism of action. Br J Cancer 90:S2-S6. (Pubitemid 38482618)
38. Otto C, Fuchs I, Kauselmann G, Kern H, Zevnik B, Andreasen P, Schwarz G, Altmann H, Klewer M, Schoor M, et al. (2009) GPR30 does not mediate estrogenic responses in reproductive organs in mice. Biol Reprod 80:34-41.
39. Powers CA, Hatala MA, and Pagano PJ (2009) Differential responses of pituitary kallikrein and prolactin to tamoxifen and chlorotrianisene. Mol Cell Endocrinol 66:93-100.
40. Revankar CM, Cimino DF, Sklar LA, Arterburn JB, and Prossnitz ER (2005) A transmembrane intracellular estrogen receptor mediates rapid cell signaling. Science 307:1625-1630. (Pubitemid 40354745)
41. Sibonga JD, Dobnig H, Harden RM, and Turner RT (1998) Effect of the high-affinity estrogen receptor ligand ICI 182,780 on the rat tibia. Endocrinology 139:3736-3742. (Pubitemid 28512252)
42. Smith CL and O'Malley BW (2004) Coregulator function: a key to understanding tissue specificity of selective receptor modulators. Endocr Rev 25:45-71. (Pubitemid 38292038)
43. Stavréus-Evers A, Parini P, Freyschuss B, Elger W, Reddersen G, Sahlin L, and Eriksson H (2001) Estrogenic influence on the regulation of hepatic estrogen receptor-α and serum level of angiotensinogen in female rats. J Steroid Biochem Mol Biol 78:83-88. (Pubitemid 32786790)
44. Sugiyama T, Galea GL, Lanyon LE, and Price JS (2010) Mechanical loading-related bone gain is enhanced by tamoxifen but unaffected by fulvestrant in female mice. Endocrinology 151:5582-5590.
45. Thomas P, Pang Y, Filardo EJ, and Dong J (2005) Identity of an estrogen membrane receptor coupled to a G protein in human breast cancer cells. Endocrinology 146:624-632. (Pubitemid 40129818)
46. Tremblay GB, Bergeron D, and Giguere V (2001) 4-Hydroxytamoxifen is an isoformspecific inhibitor of orphan estrogen- receptor-related (ERR) nuclear receptors β and γ. Endocrinology 142:4572-4575. (Pubitemid 32910264)
47. Vivacqua A, Bonofiglio D, Recchia AG, Musti AM, Picard D, Andò S, and Maggiolini M (2006) The G protein-coupled receptor GPR30 mediates the proliferative effects induced by 17β-estradiol and hydroxytamoxifen in endometrial cancer cells. Mol Endocrinol 20:631-646. (Pubitemid 43291214)
48. Wade GN, Blaustein JD, Gray JM, and Meredith JM (1993a) ICI 182,780: a pure antiestrogen that affects behaviors and energy balance in rats without acting in the brain. Am J Physiol Regul Integr Comp Physiol 265:R1392-R1398.
49. Wade GN, Powers JB, Blaustein JD, and Green DE (1993b) ICI 182,780 antagonizes the effects of estradiol on estrous behavior and energy balance in Syrian hamsters. Am J Physiol Regul Integr Comp Physiol 265:R1399-R1403.
50. Wakeling AE, Dukes M, and Bowler J (1991) A potent specific pure antiestrogen with clinical potential. Cancer Res 51:3867-3873.
51. Wallen WJ, Belanger MP, and Wittnich C (2001) Sex hormones and the selective estrogen modulator tamoxifen modulate weekly body weights and food intakes in adolescent and adult rats. J Nutr 131:2351-2357. (Pubitemid 32851880)
52. Wang C, Dehghani B, Magrisso IJ, Rick EA, Bonhomme E, Cody DB, Elenich LA, Subramanian S, Murphy SJ, Kelly MJ, et al. (2008) GPR30 contributes to estrogen-induced thymic atrophy. Mol Endocrinol 22:636-648. (Pubitemid 351397791)
53. Windahl SH, Andersson N, Chagin AS, Mårtensson UE, Carlsten H, Olde B, Swanson C, Movérare-Skrtic S, Sävendahl L, Lagerquist MK, et al. (2009) The role of the G protein-coupled receptor GPR30 in the effects of estrogen in ovariectomized mice. Am J Physiol Endocrinol Metab 296:E490-E496.
54. Wittmann BM, Sherk A, and McDonnell DP (2007) Definition of functionally important mechanistic differences among selective estrogen receptor down-regulators. Cancer Res 67:9549-9560. (Pubitemid 47535946)
55. Yin P, Kawashima K, and Arita J (2002) Direct actions of estradiol on the anterior pituitary gland are required for hypothalamus-dependent lactotrope proliferation and secretory surges of luteinizing hormone but not of prolactin in female rats. Neuroendocrinology 75:392-401. (Pubitemid 34639043)